相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
Sarah L. Craig et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Type 2 diabetes and remission: practical management guided by pathophysiology
Roy Taylor
JOURNAL OF INTERNAL MEDICINE (2021)
Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy
Emma Roth et al.
MOLECULAR METABOLISM (2021)
Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis
A. G. McCloskey et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Intra-islet GLP-1, but not CCK, is necessary for beta-cell function in mouse and human islets
Arnaldo Henrique de Souza et al.
SCIENTIFIC REPORTS (2020)
Gastrointestinal hormones and regulation of gastric emptying
Michael Camilleri
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2019)
A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
David C. Hornigold et al.
APPETITE (2018)
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
Vanita R. Aroda
DIABETES OBESITY & METABOLISM (2018)
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes
Varun Pathak et al.
PEPTIDES (2018)
Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
Jens Juul Holst et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2018)
Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs
Jens F. Rehfeld et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2017)
Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival
Dawood Khan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
The insulin-signaling pathway of the pancreatic islet is impaired in adult mice offspring of mothers fed a high-fat diet
Isabele Bringhenti et al.
NUTRITION (2016)
Cholecystokinin expression in the β-cell leads to increased β-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis
Jeremy A. Lavine et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells
Shang-lei Ning et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice
Nigel Irwin et al.
DIABETES (2015)
Differential molecular and cellular responses of GLP-1 secreting L-cells and pancreatic alpha cells to glucotoxicity and lipotoxicity
Srividya Vasu et al.
EXPERIMENTAL CELL RESEARCH (2015)
Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis
Amelia K. Linnemann et al.
MOLECULAR ENDOCRINOLOGY (2015)
Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents
J. L. Trevaskis et al.
DIABETES OBESITY & METABOLISM (2015)
(pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes
Nigel Irwin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes
Nigel Irwin et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice
N. Irwin et al.
DIABETES OBESITY & METABOLISM (2013)
Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
M. A. Nauck et al.
DIABETOLOGIA (2013)
Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes
N. Irwin et al.
DIABETOLOGIA (2012)
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
Asger Lund et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
Control of Pancreatic β Cell Regeneration by Glucose Metabolism
Shay Porat et al.
CELL METABOLISM (2011)
Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Victor A. Gault et al.
CLINICAL SCIENCE (2011)
Cholecystokinin Is Up-Regulated in Obese Mouse Islets and Expands β-Cell Mass by Increasing β-Cell Survival
Jeremy A. Lavine et al.
ENDOCRINOLOGY (2010)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
V. A. Gault et al.
DIABETOLOGIA (2007)
Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men
IM Brennan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo
BD Green et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2003)
Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin
B Ji et al.
GASTROENTEROLOGY (2001)
Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans
C Beglinger et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2001)
分享论文
